ABNORMAL PIG A EXPRESSION IN GPI DEFICIENT BLOOD CELLS
GPI 缺陷血细胞中异常猪 A 的表达
基本信息
- 批准号:2445264
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-07-01 至 2000-06-30
- 项目状态:已结题
- 来源:
- 关键词:DNA repair DNA replication T lymphocyte animal tissue erythrocytes flow cytometry gene expression gene mutation hematopoietic stem cells human subject lymphocyte proliferation membrane proteins messenger RNA molecular pathology monoclonal antibody mutant nucleotides paroxysmal nocturnal hemoglobinuria phosphatidylinositols protein sequence tissue /cell culture transfection
项目摘要
DESCRIPTION (Adapted from investigator's abstract): Paroxysmal Nocturnal
Hemoglobinuria (PNH) is a clonal acquired hematologic disorder which
results from the incomplete enzymatic assembly of glycosyl-
phosphatidylinositol (GPI) anchors used for surface protein attachment.
All PNH patients tested have a complementation Class A defect; a cDNA
(Piga) that repairs cell lines with the Class A defect has been cloned.
Analysis of the Piga gene is therefore important for the understanding
of PNH; genetic mutations of abnormal Piga expression could lead to
defective assembly of GPI anchors and ultimately to PNH. The overall
goal of the proposed research is an investigation of Piga gene mutations
and PNH, with emphasis on its abnormal expression in GPI- deficient
hematopoietic cells. The first hypothesis is that Piga gene mutations
can be identified in all PNH patients. The investigators will
characterize Piga expression in PNH patients at the mRNA and protein
level, followed by nucleotide sequencing to identify Piga mutations.
The investigators will then correlate each Piga gene mutation (genotype)
with the clinical expression of GPI-linked surface proteins (phenotype).
Three important questions are posed: (1) Do all patients with Type II
(partially GPI-deficient) erythrocytes have missense Piga mutations?;
(2) Do patients with both Type II and Type III (completely GPI-
deficient) erythrocytes have two distinct mutations?; (3) Can cells gain
or lose partial expression of GPI- like proteins in vivo? The second
hypothesis is that PNH patients have infidelity of DNA replication and
overall genetic instability which leads to mutations in the Piga gene.
This hypothesis helps to explain why PNH is an acquired disorder, why
the Piga mutations are mostly frameshift and may be multiple, and why
patients with PNH have an increased risk of leukemia. The third
hypothesis is that abnormal Piga expression leads to a cellular growth
advantage. The investigators will focus on PNH lymphocytes, and study
mechanisms by which GPI-deficient cells gain a growth advantage. The
effects of abnormal Piga expression on lymphocyte growth will also be
studied by transfection of Piga mutants and inhibition of normal Piga
expression.
描述(改编自研究者摘要):阵发性夜间
血红蛋白尿症(PNH)是一种克隆获得性血液病,
结果从糖基的不完全酶组装,
磷脂酰肌醇(GPI)锚用于表面蛋白附着。
所有接受检测的PNH患者都有一个互补A类缺陷;一个cDNA
(Piga),修复具有A类缺陷的细胞系。
因此,对Piga基因的分析对于理解
PNH; Piga表达异常的基因突变可能导致
GPI锚钉组装缺陷,最终导致PNH。整体
这项研究的目的是调查Piga基因突变
和PNH,重点是其异常表达GPI缺陷
造血细胞第一个假设是Piga基因突变
可以在所有PNH患者中发现。调查人员将
从mRNA和蛋白质水平表征PNH患者中Piga的表达
水平,随后进行核苷酸测序以鉴定Piga突变。
然后,研究人员将每个Piga基因突变(基因型)
与GPI连接的表面蛋白的临床表达(表型)。
提出了三个重要问题:(1)是否所有II型患者
(部分GPI缺陷)红细胞有错义Piga突变?
(2)II型和III型患者(完全GPI-
缺陷)红细胞有两个不同的突变?(3)细胞能否获得
或在体内失去GPI样蛋白的部分表达?第二
假设PNH患者具有DNA复制的不忠实性,
总体遗传不稳定性,导致Piga基因突变。
这一假说有助于解释为什么PNH是一种获得性疾病,为什么
Piga突变大多是移码突变,可能是多重的,为什么
PNH患者患白血病的风险增加。第三
假设Piga表达异常导致细胞生长
优势研究人员将重点关注PNH淋巴细胞,
GPI缺陷细胞获得生长优势的机制。的
异常Piga表达对淋巴细胞生长的影响也将被
通过转染Piga突变体和抑制正常Piga研究
表情
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Russell E Ware其他文献
NEUTROPENIA ASSOCIATED WITH ELEVATED TNF-α IN COMBINED IMMUNODEFICIENCY(CID). • 54
- DOI:
10.1203/00006450-199604001-00073 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Terry O Harville;Stuart S Winter;Gregory A Hanissian;James E Gern;Russell E Ware - 通讯作者:
Russell E Ware
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects
镰状细胞病患者 L-谷氨酰胺暴露的群体药代动力学分析:剂量和食物影响的评估
- DOI:
10.1007/s40262-024-01349-4 - 发表时间:
2024 - 期刊:
- 影响因子:4.5
- 作者:
Alina Sadaf;M. Dong;A. Pfeiffer;Teresa S. Latham;T. Kalfa;A. Vinks;Russell E Ware;Charles T Quinn - 通讯作者:
Charles T Quinn
CLINICAL SIGNIFICANCE OF THE ANTINUCLEAR ANTIBODY (ANA) TEST IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA (ITP). • 972
- DOI:
10.1203/00006450-199604001-00994 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Sherri A Zimmerman;Russell E Ware - 通讯作者:
Russell E Ware
Malaria prophylaxis in sickle cell anaemia: some answers, more questions
镰状细胞贫血中的疟疾预防:一些答案,更多问题
- DOI:
10.1016/s1473-3099(24)00745-x - 发表时间:
2025-06-01 - 期刊:
- 影响因子:31.000
- 作者:
Thomas N Williams;Russell E Ware - 通讯作者:
Russell E Ware
CLONAL EXPANSION OF Vβ8+ T LYMPHOCYTES IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA. • 892
- DOI:
10.1203/00006450-199604001-00914 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Denise M Adams;Thad A Howard;Russell E Ware - 通讯作者:
Russell E Ware
Russell E Ware的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Russell E Ware', 18)}}的其他基金
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10001581 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
9764461 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10223406 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10444370 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10679001 - 财政年份:2017
- 资助金额:
$ 24万 - 项目类别:
相似海外基金
A genome wide investigation into the roles of error-prone polymerases during human DNA replication
对易错聚合酶在人类 DNA 复制过程中的作用进行全基因组研究
- 批准号:
24K18094 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
DNA replication dynamics in living bacteria
活细菌中的 DNA 复制动态
- 批准号:
23K25843 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Single molecule analysis of Human DNA replication
人类 DNA 复制的单分子分析
- 批准号:
BB/Y00549X/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
MRC TS Award: Investigating the role of cardiolipin metabolism in mitochondrial DNA replication and mitochondrial division
MRC TS 奖:研究心磷脂代谢在线粒体 DNA 复制和线粒体分裂中的作用
- 批准号:
MR/X02363X/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Fellowship
The role of DONSON during DNA replication initiation
DONSON 在 DNA 复制起始过程中的作用
- 批准号:
BB/Y002458/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
The Evolution of DNA Replication Timing in Great Apes
类人猿 DNA 复制时间的演变
- 批准号:
2415012 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Continuing Grant
Cross talk between DNA replication and LPS biosynthesis during cell growth
细胞生长过程中 DNA 复制和 LPS 生物合成之间的串扰
- 批准号:
BB/Y001265/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
Pioneer factor activity in transcription and DNA replication
转录和 DNA 复制中的先锋因子活性
- 批准号:
10552309 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Pioneer factor activity in transcription and DNA replication
转录和 DNA 复制中的先锋因子活性
- 批准号:
10822405 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
How does DNA replication timing arise from the physical nature of chromatin?
DNA 复制时间是如何由染色质的物理性质产生的?
- 批准号:
23KJ0998 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for JSPS Fellows